Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.

Diphosphonates/adverse effects/therapeutic use; Humans; Jaw Diseases/chemically induced/therapy; Osteitis Deformans/drug therapy; Osteonecrosis/chemically induced/therapy; Osteoporosis/drug therapy; Risk Factors

Abstract :

[en] A potential side effect associated with bisphosphonates, a class of drugs used in the treatment of osteoporosis, Paget's disease and metastatic bone disease, is osteonecrosis of the jaw (ONJ). The incidence of ONJ in the general population is unknown; this rare condition also may occur in patients not receiving bisphosphonates. Case reports have discussed ONJ development in patients with multiple myeloma or metastatic breast cancer receiving bisphosphonates as palliation for bone metastases. These patients are also receiving chemotherapeutic agents that might impair the immune system and affect angiogenesis. The incidence or prevalence of ONJ in patients taking bisphosphonates for osteoporosis seems to be very rare. No causative relationship has been unequivocally demonstrated between ONJ and bisphosphonate therapy. A majority of ONJ occurs after tooth extraction. Furthermore, the underlying risk of developing ONJ may be increased in osteoporotic patients by comorbid diseases. Treatment for ONJ is generally conservative.

Disciplines :

General & internal medicine

Author, co-author :

Rizzoli, Rene

Burlet, Nansa

Cahall, David

Delmas, Pierre D

Eriksen, Erik Fink

Felsenberg, Dieter

Grbic, John

Jontell, Mats

Landesberg, Regina

Laslop, Andrea

More authors (5 more)

Language :

English

Title :

Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.

Publication date :

2008

Journal title :

BONE

ISSN :

8756-3282

eISSN :

1873-2763

Publisher :

Elsevier Science, New York, United States - New York

Volume :

Issue :

Pages :

841-7

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 28 August 2009

Statistics

Number of views

106 (3 by ULiège)

Number of downloads

1 (0 by ULiège)

More statistics

Scopus citations^®

186

Scopus citations^®
without self-citations

155

OpenCitations

162

OpenAlex citations

224

Bibliography

In: Marx R., and Stern D. (Eds). Oral and maxillofacial pathology: a rationale for treatment (2002), Quintessence Publishing, Hanover Park, IL
American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 137 (2006) 1144-1150
Ruggiero S.L., Fantasia J., and Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102 (2006) 433-441
In: American Association of Oral and Maxillofacial Surgeons (Ed). Position paper on bisphosphonate-related osteonecrosis of the jaws (2006), American Association of Oral and Maxillofacial Surgeons, Rosemont, IL
Khosla S., Burr D., Cauley J., Dempster D.W., Ebeling P.R., Felsenberg D., Gagel R.F., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22 (2007) 1479-1491
Bornstein M.M., Oberli K., Stauffer E., and Buser D. Bisphosphonate-associated osteonecrosis of the maxilla. Case report and review of the literature. Schweiz Monatsschr Zahnmed 116 (2006) 1035-1047
Carter G., Goss A.N., and Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust 182 (2005) 413-415
Hoefert S., and Eufinger H. Necrosis of the jaws under bisphosphonate therapy. Orthopade 35 (2006) 204-209
Khamaisi M., Regev E., Yarom N., Avni B., Leitersdorf E., Raz I., and Elad S. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 92 (2007) 1172-1175
Marx R.E., Sawatari Y., Fortin M., and Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1567-1575
Mavrokokki T., Cheng A., Stein B., and Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65 (2007) 415-423
Merigo E., Manfredi M., Meleti M., Guidotti R., Ripasarti A., Zanzucchi E., D'Aleo P., et al. Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Biomed 77 (2006) 109-117
Migliorati C.A., Schubert M.M., Peterson D.E., and Seneda L.M. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104 (2005) 83-93
Nase J.B., and Suzuki J.B. Osteonecrosis of the jaw and oral bisphosphonate treatment. J Am Dent Assoc 137 (2006) 1115-1119 quiz 1169-70
Purcell P.M., and Boyd I.W. Bisphosphonates and osteonecrosis of the jaw. Med J Aust 182 (2005) 417-418
Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
Yeo A.C., Lye K.W., and Poon C.Y. Bisphosphonate-related osteonecrosis of the jaws. Singapore Dent J 27 (2005) 36-40
Woo S.B., Hellstein J.W., and Kalmar J.R. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 (2006) 753-761
Felsenberg D., Hoffmeister B., Amling M., Mundlos S., and Fratzl P. Kiefernekrosen nach hoch dosierter Bisphosphonattherapie. Dtsch Arztebl 103 (2006) A3078-A3080
Bilezikian J.P. Osteonecrosis of the jaw - do bisphosphonates pose a risk?. N Engl J Med 355 (2006) 2278-2281
Yarom N., Yahalom R., Shoshani Y., Hamed W., Regev E., and Elad S. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 18 (2007) 1363-1370
Schwartz H.C. Osteonecrosis of the jaws: a complication of cancer chemotherapy. Head Neck Surg 4 (1982) 251-253
Woo S.B., Hellstein J.W., and Kalmar J.R. Bisphosphonates and osteonecrosis of the jaw: in response. Ann Intern Med 145 (2006) 792
Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115-1117
Hoff A.O., Toth B., Altundag K., Guarneri V., Nooka A., Desrouleaux K., Klein M., et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonates. J Bone Miner Res 20 (2005) S55
Reid I.R., Bolland M.J., and Grey A.B. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone 41 (2007) 318-320
Clezardin P., Fournier P., Boissier S., and Peyruchaud O. In vitro and in vivo antitumor effects of bisphosphonates. Curr Med Chem 10 (2003) 173-180
Croucher P., Jagdev S., and Coleman R. The anti-tumor potential of zoledronic acid. Breast 12 Suppl 2 (2003) S30-S36
Deckers M.M., van Bezooijen R.L., van der Horst G., Hoogendam J., van Der Bent C., Papapoulos S.E., and Lowik C.W. Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology 143 (2002) 1545-1553
Giraudo E., Inoue M., and Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114 (2004) 623-633
Hunziker E.B. Articular cartilage repair: problems and perspectives. Biorheology 37 (2000) 163-164
Brunsvold M.A., Chaves E.S., Kornman K.S., Aufdemorte T.B., and Wood R. Effects of a bisphosphonate on experimental periodontitis in monkeys. J Periodontol 63 (1992) 825-830
Deckers M.M., Van Beek E.R., Van Der Pluijm G., Wetterwald A., Van Der Wee-Pals L., Cecchini M.G., Papapoulos S.E., et al. Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice. J Bone Miner Res 17 (2002) 998-1007
Gerber H.P., Vu T.H., Ryan A.M., Kowalski J., Werb Z., and Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5 (1999) 623-628
Parfitt A.M. The mechanism of coupling: a role for the vasculature. Bone 26 (2000) 319-323
Weinreb M., Quartuccio H., Seedor J.G., Aufdemorte T.B., Brunsvold M., Chaves E., Kornman K.S., et al. Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys. J Periodontal Res 29 (1994) 35-40
Mundy G.R., Yoneda T., and Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin Oncol 28 (2001) 35-44
Clemons M.J., Dranitsaris G., Ooi W.S., Yogendran G., Sukovic T., Wong B.Y., Verma S., et al. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 24 (2006) 4895-4900
Coleman R.E., Major P., Lipton A., Brown J.E., Lee K.A., Smith M., Saad F., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23 (2005) 4925-4935
Reddy M.S., Weatherford III T.W., Smith C.A., West B.D., Jeffcoat M.K., and Jacks T.M. Alendronate treatment of naturally-occurring periodontitis in beagle dogs. J Periodontol 66 (1995) 211-217
Shibutani T., Inuduka A., Horiki I., Luan Q., and Iwayama Y. Bisphosphonate inhibits alveolar bone resorption in experimentally-induced peri-implantitis in dogs. Clin Oral Implants Res 12 (2001) 109-114
Shoji K., Horiuchi H., and Shinoda H. Inhibitory effects of a bisphosphonate (risedronate) on experimental periodontitis in rats. J Periodontal Res 30 (1995) 277-284
Chiandussi S., Biasotto M., Dore F., Cavalli F., Cova M.A., and Di Lenarda R. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac Radiol 35 (2006) 236-243
Hansen T., Kunkel M., Weber A., and James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35 (2006) 155-160
Grey A., and Cundy T. Bisphosphonates and osteonecrosis of the jaw. Ann Intern Med 145 (2006) 791 author reply 792
Lane N., Armitage G.C., Loomer P., Hsieh S., Majumdar S., Wang H.Y., Jeffcoat M., et al. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study. J Periodontol 76 (2005) 1113-1122
Wutzl A., Eisenmenger G., Hoffmann M., Czerny C., Moser D., Pietschmann P., Ewers R., et al. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. Wien Klin Wochenschr 118 (2006) 473-478
Borregaard N., and Herlin T. Energy metabolism of human neutrophils during phagocytosis. J Clin Invest 70 (1982) 550-557
D'Ambrosia R.D., Riggins R.S., DeNardo S.J., and DeNardo G.L. Fluoride-18 scintigraphy in avascular necrotic disorders of bone. Clin Orthop Relat Res (1975) 146-155
Palmer W.E., Rosenthal D.I., Schoenberg O.I., Fischman A.J., Simon L.S., Rubin R.H., and Polisson R.P. Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-d-glucose. Radiology 196 (1995) 647-655
Stadalnik R.C., Riggins R.L., D'Ambrosia R., and DeNardo G.L. Vascularity of the femoral head: 18fluorine scintigraphy validated with tetracycline labeling. Radiology 114 (1975) 663-666
Heiland M., Schulze D., Rother U., and Schmelzle R. Postoperative imaging of zygomaticomaxillary complex fractures using digital volume tomography. J Oral Maxillofac Surg 62 (2004) 1387-1391
Sukovic P. Cone beam computed tomography in craniofacial imaging. Orthod Craniofac Res 6 Suppl 1 (2003) 31-36 discussion 179-82
Hashimoto K., Arai Y., Iwai K., Araki M., Kawashima S., and Terakado M. A comparison of a new limited cone beam computed tomography machine for dental use with a multidetector row helical CT machine. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95 (2003) 371-377
Guerrero M.E., Jacobs R., Loubele M., Schutyser F., Suetens P., and van Steenberghe D. State-of-the-art on cone beam CT imaging for preoperative planning of implant placement. Clin Oral Investig 10 (2006) 1-7
Schulze D., Blessmann M., Pohlenz P., Wagner K.W., and Heiland M. Diagnostic criteria for the detection of mandibular osteomyelitis using cone-beam computed tomography. Dentomaxillofac Radiol 35 (2006) 232-235
Morrison W.B., Schweitzer M.E., Bock G.W., Mitchell D.G., Hume E.L., Pathria M.N., and Resnick D. Diagnosis of osteomyelitis: utility of fat-suppressed contrast-enhanced MR imaging. Radiology 189 (1993) 251-257
Shane E., Goldring S., Christakos S., Drezner M., Eisman J., Silverman S., and Pendrys D. Osteonecrosis of the jaw: more research needed. J Bone Miner Res 21 (2006) 1503-1505
In: AAE Special Committee on Bisphosphonates (Ed). Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws (2006), American Association of Endodontists, Chicago, IL
In: American College of Rheumatology (Ed). Bisphosphonate-associated osteonecrosis of the jaw (2006), American College of Rheumatology, Atlanta, GA